Rul­ing in SCO­TUS mifepri­s­tone case could lead to end­less lit­i­ga­tion, in­dus­try says

In­dus­try groups, mem­bers of Con­gress and state leg­is­la­tures are among the wave of par­ties that asked the Supreme Court on Tues­day to pre­serve the FDA’s reg­u­la­tions around the abor­tion pill mifepri­s­tone as the court gears up to hear oral ar­gu­ments in the high-pro­file case this spring.

More than 30 am­i­cus briefs, draft­ed by groups rang­ing from law­mak­ers to faith groups, were filed Tues­day in the close­ly-watched case brought by the con­ser­v­a­tive ad­vo­ca­cy or­ga­ni­za­tion Al­liance for Hip­po­crat­ic Med­i­cine that seeks to re­strict how the FDA can reg­u­late mifepri­s­tone. In­dus­try groups who filed briefs un­der­score that the Fifth Cir­cuit Court of Ap­peals’ rul­ing, which reined in the FDA’s reg­u­la­tion of the pill, could se­vere­ly desta­bi­lize the in­dus­try and open the door to end­less lit­i­ga­tion to de­ter­mine how prod­ucts can be pre­scribed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER